[1] [1] YANG T, XIONG Y L, ZENG Y F,et al. Current status of immunotherapy for non-small cell lung cancer[J/OL]. Front Pharmacol, 2022, 13: 989461[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/36313314/. DOI:10.3389/fphar.2022.989461.

[3] [3] SUN X Y, LV X M, YAN Y Y,et al. Hypoxia-mediated cancer stem cell resistance and targeted therapy[J/OL]. Biomed Pharmacother,2020, 130: 1106230[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/32791395/. DOI:10.1016/j.biopha.2020.110623.

[4] [4] ROBLES-OTEZA C, HASTINGS K, CHOI J,et al. Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer[J/OL]. J Exp Med, 2025, 222(1): e20231106[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/39585348/. DOI:10.1084/jem.20231106.

[5] [5] LI Y H, ZHANG Z, ZHOU X L,et al. The oncoprotein HBXIP enhances migration of breast cancer cells through increasing filopodia formation involving MEKK2/ERK1/2/Capn4 signaling[J]. Cancer Lett,2014, 355(2): 288-296. DOI:10.1016/j.canlet.2014.09.047.

[6] [6] ZHAO C W, YUAN G H, JIANG Y M,et al. Capn4 contributes to tumor invasion and metastasis in gastric cancerviaactivation of the Wnt/-catenin/MMP9 signalling pathways[J/OL]. Exp Cell Res,2020, 395(2): 112220[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/32777225/. DOI:10.1016/j.yexcr.2020.112220.

[7] [7] XU H X, JIAO D C, LIU A G,et al. Tumor organoids: applications in cancer modeling and potentials in precision medicine[J/OL]. J Hematol Oncol, 2022, 15(1): 58[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/35551634/. DOI:10.1186/s13045-022-01278-4.

[8] [8] KAWAHARA A, YAMAMOTO C, NAKASHIMA K,et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis[J]. Clin Cancer Res, 2010, 16(12): 3163-3170. DOI:10.1158/1078-0432.CCR-09-3239.

[9] [9] WU C J, SPECTOR S A, THEODOROPOULOS G,et al. Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer[J/OL]. Cancer Metab,2023, 11(1): 7[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/37226257/. DOI:10.1186/s40170-023-00307-1.

[10] [10] ROTTENBERG S, DISLER C, PEREGO P. The rediscovery of platinum-based cancer therapy[J]. Nat Rev Cancer, 2021, 21(1): 37-50. DOI:10.1038/s41568-020-00308-y.

[11] [11] SAW P E, LIU Q, WONG P P,et al. Cancer stem cell mimicry for immune evasion and therapeutic resistance[J]. Cell Stem Cell,2024, 31(8): 1101-1112. DOI:10.1016/j.stem.2024.06.003.

[12] [12] HUANG Q, LIU L P, XIAO D K,et al. CD44+ lung cancer stem cell-derived pericyte-like cells cause brain metastases through GPR124-enhanced trans-endothelial migration[J]. Cancer Cell,2023, 41(9): 1621-1636. DOI:10.1016/j.ccell.2023.07.012.

[13] [13] ALMARZA C, VILLALOBOS-NOVA K, TORO M A,et al. Cisplatin-resistance and aggressiveness are enhanced by a highly stable endothelin-converting enzyme-1c in lung cancer cells[J/OL]. Biol Res, 2024, 57(1): 74[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/39443981/. DOI:10.1186/s40659-024-00551-9.

[14] [14] NGUYEN A L, FACEY C O B, BOMAN B M. The significance of aldehyde dehydrogenase 1 in cancers[J/OL]. Int J Mol Sci, 2024, 26(1): 251[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/39796106/. DOI:10.3390/ijms26010251.

[15] [15] ZHENG J Y, ZHU T, ZHUO W,et al. eIF3a sustains non-small cell lung cancer stem cell-like properties by promoting YY1-mediated transcriptional activation of -catenin[J/OL]. Biochem Pharmacol,2023, 213: 115616[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/37211173/. DOI:10.1016/j.bcp.2023.115616.

[16] [16] ROWBOTHAM S P, GORUGANTHU M U L, ARASADA R R,et al. Lung cancer stem cells and their clinical implications[J/OL]. Cold Spring Harb Perspect Med, 2022, 12(4): a041270[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/34580078/. DOI:10.1101/cshperspect.a041270.

[17] [17] SAYGIN C, MATEI D, MAJETI R,et al. Targeting cancer stemness in the clinic: from hype to hope[J]. Cell Stem Cell, 2019, 24(1): 25-40. DOI:10.1016/j.stem.2018.11.017.

[18] [18] ZHANG Y M, WANG Z X, HU Q F,et al. 3D bioprinted GelMA-nanoclay hydrogels induce colorectal cancer stem cells through activating Wnt/-catenin signaling[J/OL]. Small, 2022, 18(18):e2200364[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/35229478/. DOI:10.1002/smll.202200364.

[19] [19] SATO T, VRIES R G, SNIPPERT H J,et al. Single Lgr5 stem cells build crypt-villus structuresin vitrowithout a mesenchymal niche[J]. Nature, 2009, 459(7244): 262-265. DOI:10.1038/nature07935.

[20] [20] LANCASTER M A, KNOBLICH J A. Organogenesis in a dish: modeling development and disease using organoid technologies[J/OL]. Science, 2014, 345(6194): 1247125[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/25035496/. DOI:10.1126/science.1247125.

[21] [21] LEE S Y, CHO H J, CHOI J,et al. Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC)[J/OL]. J Exp Clin Cancer Res, 2023, 42(1): 309[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/37993887/. DOI:10.1186/s13046-023-02899-4.

[22] [22] UKAI S, HONMA R, SAKAMOTO N,et al. Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell[J]. Oncogene, 2020, 39(50): 7265-7278. DOI:10.1038/s41388-020-01492-9.

[23] [23] STORR S J, CARRAGHER N O, FRAME M C,et al. The calpain system and cancer[J]. Nat Rev Cancer, 2011, 11(5): 364-374. DOI:10.1038/nrc3050.

[24] [24] ZHANG Y M, WEI S Y, CHEN Z J,et al. lncRNA FAISL inhibits calpain 2-mediated proteolysis of FAK to promote progression and metastasis of triple negative breast cancer[J/OL]. Adv Sci (Weinh),2024, 11(42): e2407493[2025-01-13]. https://pubmed.ncbi.nlm.nih.gov/39287113/. DOI:10.1002/advs.202407493.

[25] [25] BRAUN C, ENGEL M, SEIFERT M,et al. Expression of calpain Ⅰ messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type[J]. Int J Cancer,1999, 84(1): 6-9. DOI:10.1002/(sici)1097-0215(19990219)84:13.0.co;2-t.

[26] [26] LEE S J, CHOI Y L, LEE E J,et al. Increased expression of calpain 6 in uterine sarcomas and carcinosarcomas: an immunohistochemical analysis[J]. Int J Gynecol Cancer, 2007, 17(1): 248-253. DOI:10.1111/j.1525-1438.2006.00756.x.

[27] [27] DAI Z, ZHOU S L, ZHOU Z J,et al. Capn4 contributes to tumour growth and metastasis of hepatocellular carcinoma by activation of the FAK-Src signalling pathways[J]. J Pathol, 2014, 234(3): 316-328. DOI:10.1002/path.4395.

[28] [28] GU J, XU F K, ZHAO G Y,et al. Capn4 promotes non-small cell lung cancer progressionviaupregulation of matrix metalloproteinase 2[J/OL]. Med Oncol, 2015, 32(3): 51[2025-01-13]. http://dx.doi.org/10.1007/s12032-015-0500-7. DOI:10.1007/s12032-015-0500-7.